The U.S. Court of Appeals for the Federal Circuit in a precedential decision yesterday affirmed a Patent Trial and Appeal Board (PTAB) decision that Teva Pharmaceuticals had failed to prove Corcept Therapuetics’ U.S. Patent No. 10,195,214 would have been obvious. The patent covers methods of treating Cushing’s syndrome, a disease caused by excessive levels of the naturally occurring steroid hormone, cortisol. Chief Judge Moore authored the opinion.
Recent Posts
- A New Era of Copyright Litigation in Hollywood: Revisiting Pirates of the Caribbean One Year Later
- Federal Circuit Vacates TTAB Decision as Arbitrary and Capricious
- ‘I Want to Thank You’: Who and What IP Stakeholders are Giving Thanks for This Year
- SCOTUS Declines Solving Circuit Split on Awarding Avoided Costs in Trade Secret Cases
- Supreme Court Again Denies Inventor’s Bid to End Alice/Mayo